State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
Phytomedicine. 2019 Mar 1;55:302-309. doi: 10.1016/j.phymed.2018.09.215. Epub 2018 Sep 27.
There is an increasing of reports describing the efficacy of neuroprotective small molecule in Parkinson's disease (PD) models. Ideally, the choice of pushing drug candidates to clinical trial should be based on an unbiased assessment of all available data. Systematic review uses a methodical approach to minimize the bias in the selection of studies for inclusion, providing a comprehensive understanding of the drug's effects on multiple animal models with different mechanism. To our knowledge, such assessments of baicalein, which is a candidate neuroprotective drug with efficacy in PD, have not been fully conducted.
To provide a comprehensive understanding of baicalein's effects on different animal models with different mechanism by using a methodical approach to minimize the bias in the selection of studies.
In this study, we used a systematic review method to comprehensively assess the efficacy of baicalein in animal PD models. By using electronic and manual search for the literatures, we identified studies describing the efficacy of baicalein in animal models of PD.
We identified 16 studies describing the efficacy of baicalein in animal models of PD. The methodological quality of all preclinical trials is ranged from 2 to 5. 16 studies involved 4 main kinds of PD animal models. They are MPP+-induced, rotenone-induced, 6-OHDA-induced and acrolein-induced PD models, respectively. The protective effects of baicalein were studied mainly focusing on the anti-oxidative, anti-apoptotic, and anti-inflammatory action. Beyond that, there are 2 articles describing the effects of baicalein on neurotransmitter balance in the basal ganglia, and 2 articles reporting the effects in decreasing synuclein aggregation.
The results demonstrated the neuroprotective effects of baicalein in PD experimental animals and analyzed the pharmacological mechanism. The information will be useful for the further development of baicalein into anti-PD agent and provide unbiased evidence for the conduct of clinical trials. In addition, such evaluation based on animal experiments can give us a general introduction to different animal models of PD, either guiding the further model tests, or avoiding the unnecessary replication.
越来越多的报告描述了神经保护小分子在帕金森病（PD）模型中的疗效。理想情况下，将候选药物推向临床试验的选择应该基于对所有可用数据的无偏评估。系统评价采用系统方法来最小化纳入研究的选择偏倚，从而全面了解药物对具有不同机制的多种动物模型的影响。据我们所知，尚未对黄芩素作为具有 PD 疗效的候选神经保护药物进行全面评估。
通过采用系统方法来最小化纳入研究选择的偏倚，全面了解黄芩素对具有不同机制的不同动物模型的影响。
本研究采用系统评价方法全面评估黄芩素在动物 PD 模型中的疗效。通过电子和手动搜索文献，我们确定了描述黄芩素在 PD 动物模型中疗效的研究。
我们确定了 16 项描述黄芩素在 PD 动物模型中疗效的研究。所有临床前试验的方法学质量从 2 到 5 不等。16 项研究涉及 4 种主要的 PD 动物模型，分别为 MPP+诱导、鱼藤酮诱导、6-OHDA 诱导和丙烯醛诱导的 PD 模型。黄芩素的保护作用主要集中在抗氧化、抗凋亡和抗炎作用上。此外，还有 2 篇文章描述了黄芩素对基底神经节中神经递质平衡的影响，2 篇文章报道了其减少突触核蛋白聚集的作用。
结果表明黄芩素对 PD 实验动物具有神经保护作用，并分析了其药理机制。这些信息将有助于黄芩素进一步开发为抗 PD 药物，并为临床试验的进行提供无偏倚的证据。此外，基于动物实验的这种评估可以为我们提供 PD 不同动物模型的一般介绍，无论是指导进一步的模型测试，还是避免不必要的重复。
